- Positive Tisotumab Vedotin Phase 2 innovaTV
204 Data in Recurrent or Metastatic Cervical Cancer to be Featured
in Late-Breaking Oral Presentation -
- Data to be Presented from 11 Additional
Abstracts Covering Marketed or Clinical-Stage Programs -
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the
presentation of new data from its broad pipeline of marketed and
investigational therapies at the European Society for Medical
Oncology (ESMO) Virtual Congress 2020, taking place September
19-21. Twelve abstracts, including a late-breaking abstract
accepted for oral presentation featuring data from the positive
tisotumab vedotin phase 2 innovaTV 204 clinical trial in recurrent
or metastatic cervical cancer, will highlight the company’s
continued progress in advancing research in cancers that have a
significant unmet need.
“At the ESMO Virtual Congress, we will be sharing important
updates from our broad oncology portfolio of both marketed and
investigational therapies, including an oral presentation of full
data from the phase 2 trial evaluating tisotumab vedotin in
recurrent or metastatic cervical cancer,” said Roger Dansey, M.D.,
Chief Medical Officer at Seattle Genetics. “In addition, we will
present data describing real-world outcomes for patients with
HER2-positive breast cancer with brain metastases, as well as
additional analyses of the impact of TUKYSA on clinical outcomes
and quality of life for patients in the HER2CLIMB trial. As
illustrated by several trials in progress presentations, we
continue to advance the development of our programs across a range
of unmet medical needs.”
The abstract titles published in advance of the ESMO Congress
can be found here. All data presentations will be available via
on-demand view starting on Thursday, September 17, 2020.
Details of Key Seattle Genetics
Presentations at ESMO Virtual Congress 2020:
Abstract Title
Abstract # / Presentation
#
Presentation Type /
Date
Presenter
Completed Clinical
Trials
Tisotumab Vedotin
Tisotumab vedotin (TV) in previously
treated recurrent or metastatic cervical cancer (r/mCC): results
from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study
#3435/#LBA32
Late-breaking oral presentation / Monday,
Sept. 21 at 17:04 CET
RL. Coleman
Tucatinib (TUKYSA®)
Impact of Tucatinib on Health-Related
Quality of Life (HRQoL) in Patients with HER2+ Metastatic Breast
Cancer (MBC) with and without Brain Metastases (BM)
#2067/#275O
Oral presentation / Monday, Sept. 21 at
12:42 CET
V. Mueller
Impact of Tucatinib on Progression-Free
Survival in Patients with HER2+ Metastatic Breast Cancer and Brain
Metastases
#2073/#293P
Poster presentation / Thursday, Sept.
17
T. Bachelot
Real-world outcomes among HER2+ metastatic
breast cancer patients with brain metastases
#4262/#308P
Poster presentation / Thursday, Sept.
17
N. Lindegger
Physiologically Based Pharmacokinetic
(PBPK) Modeling of the Central Nervous System (CNS)
Pharmacokinetics of Tucatinib in Patients with Breast Cancer Brain
Metastasis
#3068/#295P
Poster presentation / Thursday, Sept.
17
A. Lee
Enfortumab Vedotin (PADCEV®)
EV-201: Long-term results of enfortumab
vedotin monotherapy for locally advanced or metastatic urothelial
cancer previously treated with platinum and PD-1/PD-L1
inhibitors
#2223/#746P
Poster presentation / Thursday, Sept.
17
P. O’Donnell
Trials-in-Progress
Enfortumab Vedotin (PADCEV)
Study EV-302: A 3-arm, open-label,
randomized phase 3 study of enfortumab vedotin plus pembrolizumab
and/or chemotherapy, versus chemotherapy alone, in untreated
locally advanced or metastatic urothelial cancer
#2065/#798TiP
Poster presentation / Thursday, Sept.
17
M. van der Heijden
Tucatinib (TUKYSA)
MOUNTAINEER: Open-Label, Phase 2 Study of
Tucatinib Combined with Trastuzumab for HER2-Positive Metastatic
Colorectal Cancer
#2070/#523TiP
Poster presentation / Thursday, Sept.
17
J. Strickler
HER2CLIMB-02: A randomized, double-blind,
phase 3 study of tucatinib or placebo with T DM1 for unresectable
locally-advanced or metastatic HER2+ breast cancer
#2068/#353TiP
Poster presentation / Thursday, Sept.
17
S. Hurvitz
Other Investigational Therapies
innovaTV 208: New Weekly Dosing Cohort in
the Phase 2 Study of Tisotumab Vedotin in Platinum-Resistant
Ovarian Cancer
#2221/#882TiP
Poster presentation / Thursday, Sept.
17
SV. Blank
SGNLVA-002: Single arm, open-label, phase
1b/2 study of ladiratuzumab vedotin (LV) in combination with
pembrolizumab for first-line treatment of triple-negative breast
cancer
#2075/#357TiP
Poster presentation / Thursday, Sept.
17
J. Cortez
SGNTGT-001: A phase 1 study of SGN‑TGT, an
effector-function enhanced monoclonal antibody (mAb), in advanced
malignancies
#2076/#1074TiP
Poster presentation / Thursday, Sept.
17
E. Garralda
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that
discovers, develops and commercializes transformative cancer
medicines to make a meaningful difference in people’s lives.
ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab
vedotin-ejfv) use the Company’s industry-leading antibody-drug
conjugate (ADC) technology. ADCETRIS is approved in certain
CD30-expressing lymphomas, and PADCEV is approved in certain
metastatic urothelial cancers. TUKYSA® (tucatinib), a small
molecule tyrosine kinase inhibitor, is approved in certain
HER2-positive metastatic breast cancers. The company is
headquartered in the Seattle, Washington area, with locations in
California, Switzerland and the European Union. For more
information on our robust pipeline, visit www.seattlegenetics.com
and follow @SeattleGenetics on Twitter.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the Company’s
pipeline and the advancement of its development programs across a
range of unmet medical needs. Actual results or developments may
differ materially from those projected or implied in these
forward-looking statements. Factors that may cause such a
difference include the difficulty and uncertainty of pharmaceutical
product development, the risk of adverse events or safety signals,
the inability to show sufficient activity in clinical trials and
the possibility of adverse regulatory actions. More information
about the risks and uncertainties faced by Seattle Genetics is
contained under the caption “Risk Factors” included in the
Company’s Quarterly Report on Form 10-Q for the quarter ended June
30, 2020 filed with the Securities and Exchange Commission. Seattle
Genetics disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200827005253/en/
Media: Monique Greer (425) 527-4641 mgreer@seagen.com
Investors: Peggy Pinkston (425) 527-4160
ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From May 2023 to May 2024